Beckman Coulter

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Beckman Coulter sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).

18 total trials none currently recruiting 15 completed top decile by trial count

Beckman Coulter: 18 sponsored US clinical trials, none currently recruiting.

Beckman Coulter sponsors 18 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 15 completed. The most-studied condition in this pipeline is Leukemia/Lymphoma, with 1 trials.

Top-decile sponsor footprint

Beckman Coulter ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 48/100

15 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

18 total, page 1 of 1

COMPLETED

Access BNP Clinical Performance Evaluation: Testing and Clinical Concordance Study

NCT07217431
COMPLETED

Access BNP Clinical Enrollment Study

NCT06624293
COMPLETED

Access MeMed BV Assay Clinical Study Collection Protocol - Infectious Adult and Pediatric Cohorts

NCT06379061
COMPLETED

DxFLEX 10C Clinical Study

NCT05467449
COMPLETED

Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC

NCT04804306
COMPLETED

Sepsis Post Market Clinical Utility Simple Endpoint Study - Indiana University Hospital

NCT04819035
COMPLETED

Feasibility Study of Hematology Parameters in COVID-19 Disease

NCT04816630
COMPLETED

Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Washington University

NCT04353388
COMPLETED

Access Natriuretic Peptide Assay(s) Pivotal - Emergency Department Subject Enrollment and Specimen Collection

NCT04169815
COMPLETED

Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Baylor S&W

NCT04291417
COMPLETED

Evaluation of ClearLLab Leukemia and Lymphoma Panels

NCT03413644
COMPLETED

Evaluation of Prealbumin Levels in Men With Low-T

NCT03313635
COMPLETED

Evaluation of Monocyte Volume Distribution Width (MDW) for Early Detection of Sepsis

NCT03145428
COMPLETED

Clinical Performance Evaluation of AMH Assay

NCT03131388
TERMINATED

Clinical Performance Evaluation of DxN CMV Assay

NCT03127787
COMPLETED

Use of Blood Biomarkers and Biomarker Index to Aid in the Diagnosis of Obstructive Sleep Apnea (OSA)

NCT03122483
TERMINATED

Clinical Performance Evaluation of DxN HBV Assay

NCT03123159
TERMINATED

Clinical Performance Evaluation of DxN HCV Assay

NCT03125408

Therapeutic Areas

Leukemia/Lymphoma 1

How the Beckman Coulter archive is shaped

18 indexed studies, none listed as recruiting (0% open); 15 completed (83%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Leukemia/Lymphoma (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Beckman Coulter: archived-pipeline peers nationwide

Peers matched on 18 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Beckman Coulter sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%10%20%30%40% Total trials Recruiting share Beckman CoulterADC Therapeutics S.A.Akros PharmaAO Clinical Investigation and Publishing DocumentationAO Innovation Translation Center10xBio22nd Century Group23andMe3-C Institute for Social Development
Beckman Coulter sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Beckman Coulter sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 18 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Beckman Coulter page

18 registered trials is a research-attention snapshot, not an endorsement of Beckman Coulter or any single study.

  • None of Beckman Coulter's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Leukemia/Lymphoma is the condition Beckman Coulter studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Leukemia/Lymphoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Beckman Coulter pipeline card: 18 registered trials from official public datasets.Report a data error.